Log in

NASDAQ:PATH - NuPathe Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:PATH
CUSIPN/A
Phone+1-610-2320800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive PATH News and Ratings via Email

Sign-up to receive the latest news and ratings for PATH and its competitors with MarketBeat's FREE daily newsletter.


NuPathe (NASDAQ:PATH) Frequently Asked Questions

What is NuPathe's stock symbol?

NuPathe trades on the NASDAQ under the ticker symbol "PATH."

Has NuPathe been receiving favorable news coverage?

Press coverage about PATH stock has trended somewhat positive on Thursday, according to InfoTrie. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NuPathe earned a news impact score of 0.9 on InfoTrie's scale. They also assigned media stories about the healthcare company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for NuPathe.

What other stocks do shareholders of NuPathe own?

What is NuPathe's official website?

The official website for NuPathe is http://www.nupathe.com/.

How can I contact NuPathe?

NuPathe's mailing address is 7 Great Valley Pkwy Ste 300, MALVERN, PA 19355-1425, United States. The healthcare company can be reached via phone at +1-610-2320800.


MarketBeat Community Rating for NuPathe (NASDAQ PATH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  122
MarketBeat's community ratings are surveys of what our community members think about NuPathe and other stocks. Vote "Outperform" if you believe PATH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PATH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Featured Article: Return on Equity (ROE)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel